Obinutuzumab in chronic lymphocytic leukemia.
Obinutuzumab is the second next-generation monoclonal anti-CD20 antibody (after ofatumumab) to enter clinical practice in chronic lymphocytic leukemia. Its superiority in association with chlorambucil as compared with chlorambucil alone has led to its approval as a first-line treatment for chronic lymphocytic leukemia, for patients who are not candidates for a more intensive treatment.
Lymphoid Malignancies Unit, Henri Mondor University Hospital, Créteil, France.
Jehan
J
Dupuis
D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D010597:Pharmacogenetics; D011358:Product Surveillance, Postmarketing; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C543332:obinutuzumab
anti-CD20; chronic lymphocytic leukemia; infusion-related reactions; minimal residual disease; obinutuzumab